Baystreet.ca - Plus Fails to Find Traction on Licensing Agreement
Plus Therapeutics, Inc. (NASDAQ: PSTV) saw its shares continue static Friday, as the clinical-stage pharmaceutical company announced it has expanded its supply agreement with Biocept by acquiring an option to exclusively license Biocept's CNSide, a CSF-based ...